<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508179</url>
  </required_header>
  <id_info>
    <org_study_id>7HP-101a</org_study_id>
    <nct_id>NCT04508179</nct_id>
  </id_info>
  <brief_title>A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Placebo-controlled, Within-Cohort Randomized, Double-blind, Single and Multiple Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of 7HP349 in Normal Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>7 Hills Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Frontage Clinical Services, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>7 Hills Pharma, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetics of 7HP349, an&#xD;
      allosteric integrin activator, in healthy male subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human (FIH) study consists of a placebo-controlled, sequential, dose escalation&#xD;
      study to determine the safety, tolerability and pharmacokinetics (PK) of 7HP349 following&#xD;
      single and multiple oral dose administration to healthy male subjects, with a separate,&#xD;
      open-label food effect cohort at the optimal pharmacokinetic dose (OPD). The study will be&#xD;
      carried out in 3 parts.&#xD;
&#xD;
      Part A: This is a placebo-controlled, within-cohort randomized, double-blind, sequential,&#xD;
      single ascending dose (SAD) escalation study to determine the safety, tolerability and PK of&#xD;
      7HP349 following administration of single oral doses in healthy male subjects, and to define&#xD;
      the OPD of 7HP349.&#xD;
&#xD;
      Part B: This is a placebo-controlled, within-cohort randomized, double-blind, sequential,&#xD;
      multiple ascending dose (MAD) escalation study to determine the safety, tolerability and PK&#xD;
      of 7HP349 following up to 5 once daily oral doses in healthy male subjects.&#xD;
&#xD;
      Part C: This is a randomized, open label, two-treatment, three-period, crossover study to&#xD;
      evaluate the effect of the fed or fasting prandial state on the single dose PK of 7HP349.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Actual">October 25, 2021</completion_date>
  <primary_completion_date type="Actual">October 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study consists of three parts, Part A, Part B and Part C, which will be undertaken sequentially. Part A is a SAD study to determine the safety, tolerability and PK of 7HP349 in healthy male subjects, and to define the OPD. Part B is a MAD study to determine the safety, tolerability and PK of 7HP349 following up to 5 once daily oral doses in healthy male subjects. Part C is a crossover study to evaluate the effect of the fed or fasting prandial state on the single dose PK of 7HP349.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of 7HP349 in healthy male subjects as assessed by incidence of treatment-emergent adverse events according to CTCAE v5.0 criteria</measure>
    <time_frame>17 days</time_frame>
    <description>Safety assessments will include evaluation of incidence of treatment-emergent adverse events (AEs) according to CTCAE v5.0 criteria, including vital signs, resting electrocardiogram (ECG) parameters, standard hematology, chemistry, urinalysis and other tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 7HP349 in healthy male subjects as assessed by maximum plasma concentration (Cmax) towards determination of the optimal pharmacokinetic dose (OPD)</measure>
    <time_frame>17 days</time_frame>
    <description>Determination of maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 7HP349 in healthy male subjects as assessed by plasma exposure (AUClast and/or AUCinf) towards determination of the optimal pharmacokinetic dose (OPD)</measure>
    <time_frame>17 days</time_frame>
    <description>Determination of plasma exposure (AUClast and/or AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 7HP349 in healthy male subjects as assessed by exposure in urine towards determination of the optimal pharmacokinetic dose (OPD)</measure>
    <time_frame>17 days</time_frame>
    <description>Determination of exposure in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 7HP349 in healthy male subjects as assessed by renal clearance (CLr) towards determination of the optimal pharmacokinetic dose (OPD)</measure>
    <time_frame>17 days</time_frame>
    <description>Determination of renal clearance (CLr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma concentration (Cmax) in fed individuals</measure>
    <time_frame>28 days</time_frame>
    <description>Fed prandial state, determination of maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma exposure (AUClast and/or AUCinf) in fed individuals</measure>
    <time_frame>28 days</time_frame>
    <description>Fed prandial state, determination of plasma exposure (AUClast and/or AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma concentration (Cmax) in fasted individuals</measure>
    <time_frame>28 days</time_frame>
    <description>Fasted prandial state, determination of maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma exposure (AUClast and/or AUCinf) in fasted individuals</measure>
    <time_frame>28 days</time_frame>
    <description>Fasted prandial state, determination of plasma exposure (AUClast and/or AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of the Geometric Mean Ratio (GMR) of the maximum plasma concentration (Cmax) in fed vs. fasted individuals</measure>
    <time_frame>28 days</time_frame>
    <description>Determination of Geometric Mean Ratio (GMR) of fed:fasted Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of the Geometric Mean Ratio (GMR) of the plasma exposure (AUClast and/or AUCinf) in fed vs. fasted individuals</measure>
    <time_frame>28 days</time_frame>
    <description>Determination of Geometric Mean Ratio (GMR) of fed:fasted AUClast and/or AUCinf</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>7HP349 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (3-period cross-over)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7HP349 Single Ascending Dose</intervention_name>
    <description>Part A: 7HP349 Capsules, Single Ascending Dose (SAD)</description>
    <arm_group_label>7HP349 Capsules</arm_group_label>
    <other_name>7HP349 SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7HP349 Multiple Ascending Dose</intervention_name>
    <description>Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)</description>
    <arm_group_label>7HP349 Capsules</arm_group_label>
    <other_name>7HP349 MAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Single Ascending Dose</intervention_name>
    <description>Part A: Placebo Capsules, Single Ascending Dose (SAD)</description>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <other_name>Placebo SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Multiple Ascending Dose</intervention_name>
    <description>Part B: Placebo Capsules, Multiple Ascending Dose (MAD)</description>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <other_name>Placebo MAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7HP349 Food Effect</intervention_name>
    <description>Part C: 7HP349 Capsules, Food Effect</description>
    <arm_group_label>7HP349 Capsules</arm_group_label>
    <other_name>7HP349 FE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males between the ages of 18 and 45 years, inclusive&#xD;
&#xD;
          -  Normal clinical chemistry, hepatic function, hematology, thyroid function&#xD;
&#xD;
          -  Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 60 kg&#xD;
&#xD;
          -  Agree to refrain from consuming products containing grapefruit, pomelo, star fruit or&#xD;
             Seville oranges for at least 7 days before the first dose of study drug until the&#xD;
             final discharge evaluation&#xD;
&#xD;
          -  Positive immune status as defined in serum as measles, mumps, varicella-zoster viruses&#xD;
             (VZR); Antibody Index (AI) ≥ 1.1, and positive Rubella: AI ≥ 1.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant history of disorders, infections or drug hypersensitivity as&#xD;
             determined by the Investigator&#xD;
&#xD;
          -  History of malignancy, with the exception of cured basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C antibody&#xD;
&#xD;
          -  Current treatment or treatment within 30 days with another investigational medication&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Frontage Clinical Services Inc.</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

